Latest Topiramate Stories

Retail Availability Expected Within 90 Days MOUNTAIN VIEW, Calif., April 16, 2013 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that the U.S. Food and Drug Administration (FDA) has approved its amendment and modification to the Risk Evaluation and Mitigation Strategy (REMS) for Qsymia(® )(phentermine and topiramate extended-release) capsules CIV. The amendment, submitted in October 2012, allows Qsymia( )to be dispensed through certified retail pharmacies, in addition to...

10%-15% WEIGHT LOSS AMONG OBESE OR OVERWEIGHT MEDICARE PATIENTS COULD SAVE BILLIONS MOUNTAIN VIEW, Calif., March 25, 2013 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS) announced today that a new study demonstrates that effective medical treatment providing 10% to 15% weight loss could lead to significant improvements in Medicare spending by reversing or reducing significant health consequences such as type 2 diabetes, hypertension and dyslipidemia in obese or overweight patients. The...

If you or anyone you know has taken Topamax during a pregnancy, the attorneys at d'Oliveira & Associates urge you to contact them immediately. (PRWEB) March 23, 2013 Topamax is a popular anticonvulsant prescription drug manufactured by the Johnson & Johnson subsidiary Ortho-McNeil Pharmaceutical. Originally approved by The U.S. Food and Drug Administration (FDA) in 1996 to treat persons experiencing epileptic seizures, the drug has since been approved as an anti-migraine drug...

MAPLE GROVE, Minn., March 11, 2013 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. (Upsher-Smith), a privately held, specialty pharmaceutical company committed to the development of new treatments for diseases of the central nervous system (CNS), is proud to sponsor emerging data for three investigational drug programs in epilepsy at the 65(th) Annual Meeting of the American Academy of Neurology (AAN) in San Diego, CA, March 16-23, 2013. Upsher-Smith's CNS pipeline consists of...

"Q AND ME" ENCOURAGES LIFESTYLE SKILLS TO AID IN LASTING WEIGHT LOSS MOUNTAIN VIEW, Calif., March 7, 2013 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS) announced today the launch of the Q and Me(TM) app, a no-cost mobile app available through iTunes and Google Play Store designed to help patients meet their weight loss goals. Q and Me can be used by anyone wanting to develop skills that can lead to lasting weight loss. The Q and Me Patient Support Program (www.QandMEsupport.com) is...

GET STARTED! AND SAVE NOW! PROGRAMS PROVIDE APPROPRIATE NEW PATIENTS UP TO $150 SAVINGS* MOUNTAIN VIEW, Calif., March 5, 2013 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced a new program offering eligible patients a discount on Qsymia(®) (phentermine and topiramate extended-release) capsules CIV for a limited time. The Save Now! Program is available online exclusively at www.qsymia.com and provides patients with the opportunity to pay no more than $75 for 30 days of...

MOUNTAIN VIEW, Calif., Feb. 1, 2013 /PRNewswire/ -- VIVUS, Inc. (Nasdaq: VVUS) announced today the publication of a study concluding that weight loss resulting from treatment with Qsymia(TM) (phentermine and topiramate extended-release) capsules CIV led to significant improvements in cholesterol, blood pressure and triglycerides in obese and overweight patients experiencing one or more of these associated conditions. The improvements were significantly greater among patients who lost...

Lawrence LeBlond for redOrbit.com - Your Universe Online It is well-known that children and teens can suffer from debilitating migraines as much as adults do. And many of these younger sufferers are often prescribed the same drugs and doses that adults receive for their pulse-pounding headaches. But two recent reviews of pediatric migraine research are digging up some troubling news. According to these reviews, there’s no evidence that most drugs currently prescribed to treat...

MOUNTAIN VIEW, Calif., Dec. 20, 2012 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that Express Scripts, among the country's largest Pharmacy Benefit Managers (PBMs), has added Qsymia(TM) to its national pharmacy formularies, allowing for coverage where available by benefit design of the first new FDA-approved medication commercially available in the U.S. in over a decade for the treatment of chronic weight management. Express Scripts provides the formulary design,...

Medication development efforts for cocaine dependence have yet to result in an FDA approved treatment. The powerful rewarding effects of cocaine, the profound disruptive impact of cocaine dependence on one's lifestyle, and the tendency of cocaine to attract people who make poor life choices and then exacerbate impulsive behavior all make cocaine a vexing clinical condition. In this battle, many candidate pharmacotherapies have been tested, but none have succeeded sufficiently to be adopted...